J . HANLEY,* A. MCKERNAN,† M. D. CREAGH,‡ S. CLASSEY,§ P. MCLAUGHLIN,¶ N. GODDARD,¶ P. J . BRIGGS,* S. FROSTICK,** P. GIANGRANDE,†† J . WILDE,‡‡ J . THACHIL§§ and P. CHOWDARY¶ ON BEHALF OF THE MUSCULOSKELETAL WORKING PARTY OF THE UKHCDO *Haemophilia Centre, Royal Victoria Infirmary, Newcastle upon Tyne; †Department of Haematology, Derby Hospitals NHS Foundation Trust, Derby; ‡Haemophilia Centre...

Factor VIII-containing materials were administered to four severely affected haemophiliacs twice weekly in doses calculated to raise the factor VIII level to either 15% or 30% of average normal. The pooled results from those patients with statistically similar baseline bleeding frequencies showed a significant reduction in bleeding frequency on both doses in the first 48 hours. The 30% dose pro...

Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) IX B). Prophylaxis – regular administration therapeutic products to maintain hemostasis and prevent bleeding mainstream treatment. Addressing development scientific evidence for administrating prophylaxis goal this review. modality choice people with sev...

background: considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. the objective of this study was to assess the safety, efficacy and non inferiority of safacto (recombinant factor viii) compared with plasma-derived factor in the treatment of hemophilia a. methods: 10 ...

INTRODUCTION New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood. AIM To identify the relative importance of frequency of administration, ef...

Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 ...

Background: Children with hemophilia are prone to a variety of psychological problems due to some limitations associated with the disease. We aimed to compare the cognitive, emotional, and behavioral problems of children with hemophilia to healthy children. Methods: This study was performed on 65 children with hemophilia and 65 healthy individuals as the control group who were between the ages...